Clinical Trials
Peptide clinical trial explorer.
Search public clinical trials by peptide, sponsor, indication, phase, and status. Data sourced from public trial registries.
Demonstration data — verify all information before publication. Not medical or investment advice.
| NCT ID | Title | Phase | Status | Sponsor | Indication | Primary completion |
|---|---|---|---|---|---|---|
| NCT03574597 | SUSTAIN — semaglutide long-term outcomes | Phase 3 | Completed | Novo Nordisk | Type 2 Diabetes | 8/1/2018 |
| NCT03693430 | STEP — semaglutide in obesity | Phase 3 | Completed | Novo Nordisk | Obesity | 3/1/2020 |
| NCT04184622 | SURPASS — tirzepatide in T2D | Phase 3 | Completed | Eli Lilly | Type 2 Diabetes | 2/1/2021 |
| NCT04255433 | SURMOUNT — tirzepatide in obesity | Phase 3 | Completed | Eli Lilly | Obesity | 4/1/2022 |
| NCT05929066 | TRIUMPH — retatrutide obesity program | Phase 3 | Recruiting | Eli Lilly | Obesity | 11/1/2026 |
| NCT05567796 | REDEFINE — CagriSema in obesity | Phase 3 | Active, not recruiting | Novo Nordisk | Obesity | 1/1/2026 |
| NCT06077864 | SYNCHRONIZE-1 — survodutide in obesity | Phase 3 | Recruiting | Zealand Pharma | Obesity | 6/1/2027 |
| NCT05669599 | MariTide obesity Phase 2 | Phase 2 | Active, not recruiting | Amgen | Obesity | 6/1/2026 |
| NCT05203237 | VK2735 obesity Phase 2 | Phase 2 | Active, not recruiting | Viking Therapeutics | Obesity | 12/1/2025 |
| NCT05989711 | IMPACT — pemvidutide in MASH | Phase 2 | Recruiting | Altimmune | MASH | 4/1/2026 |